News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Roche’s EPO Fails To Help Heart Attack Victims In Study
March 30, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ORLANDO, Fla., March 30 (Reuters) - High doses of erythropoietin, which boosts red blood cells, failed to improve the heart's pumping function in a study of heart attack victims, while its use also raised safety concerns.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Roche
MORE ON THIS TOPIC
Insights
From Nuclear Winter to Renewal: Biotech Investing for 2026
January 8, 2026
·
1 min read
·
Jennifer Smith-Parker
Rare diseases
Crinetics Advances Potential Neurocrine Competitor With Fresh Data and Money
January 7, 2026
·
2 min read
·
Dan Samorodnitsky
Infectious disease
GSK, Ionis Achieve Functional Cure in Hepatitis B Studies, Clearing Path for FDA Run
January 7, 2026
·
2 min read
·
Tristan Manalac
Stomach cancer
Jazz’s Ziihera Shows ‘Practice-Changing’ Efficacy in Stomach Cancer
January 7, 2026
·
2 min read
·
Tristan Manalac
